Business & Tech
La Mesa's Regen BioPharma at Work on Breast Cancer Vaccine
Regan will conduct research using gene technology developed by Benitec Biopharma.
Could a vaccine to fight breast cancer be developed in La Mesa?
At the very least La Mesa company Regen BioPharma could play a role, reports the San Diego Daily Transcript. Regen's logo includes the words “fast forwarding stem-cell medicine.”
Regen, a subsidiary of Bio-Matrix Scientific Group (OTC: BMSN), has a licensing agreement with Benitec Biopharma (ASX: BLT) for vaccines that can be developed using gene technology shaped by Benitec.
Interested in local real estate?Subscribe to Patch's new newsletter to be the first to know about open houses, new listings and more.
Ever worked in a laboratory? Help us decipher the technology they'll be using, according to the report: “the application of ddRNAi to silence indoleamine 2,3 - dioxygenase (IDO) in dendritic cells.”
Huh? Let's break it down a bit. IDO may cause immune suppression and is present when there is cancer. In preliminary work, Regan has shown that altering the cells with ddRNAi could make it more likely for use in the development of a vaccine to fight cancer.
Interested in local real estate?Subscribe to Patch's new newsletter to be the first to know about open houses, new listings and more.
According to a news release, Dr. David Koos, Regen's CEO, said, the work could lead to “an immune-based, non-toxic, cancer treatment initially targeting breast cancer."
The science behind the research has been examined in The Journal of Cancer.
Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.
